Perelman School of Medicine at the University of Pennsylvania

Center for Research on Reproduction and Women's Health

Andrea Facciabene

faculty photo
Research Assistant Professor of Radiation Oncology
Mouse Core Supervisor, Ovarian Cancer Research Center (Feb, 2009 to pres), University of Pennsylvania School of Medicine, Philadelphia, PA
Department: Radiation Oncology

Contact information
University of Pennsylvania Perelman School of Medicine
Department of Radiation Oncology
Smilow Center for Translational Research Rm. 8-133
3400 Civic Center Blvd., Bldg 421
Philadelphia, PA 19104
Office: 215-746-7071
Fax: 215-898-0090
Education:
BS (Pharmaceutical Biotechnology Science (summa cum laude))
University of Bologna, Italy (Thesis: Centre of Drug Discovery, L'Aquila, Italy) Summa Cum Laude, 2000.
PhD (Cancer Rsrch & Molecular Biol & Biotechnology)
Univ of Perugia in collaboration with the Univ of California San Diego, San Diego, CA (coursework 11/01-5/05 in Italy; exam in CA 2/06), 2006.
Post-Graduate Training
Research Fellowship, Gene Therapy, IRBM, Istituto Ricerche Biologie Medicina-P. Angeletti (Merck & Co) Rome, Italy (Feb, 00 to Nov, 01) , 2000-2002.
Postdoctoral Research Fellowship, University of California San Diego, Department of Cancer Research San Diego, CA (5/05 - 5/06) • Development of MUC1 cancer vaccine , 2005-2006.
Postdoctoral Research Fellowship, University of Pennsylvania, Center for Ovarian Cancer Research 5/06-8/07 , 2006-2007.
Permanent link
 
> Perelman School of Medicine   > Faculty   > Details

Description of Research Expertise

Dr. Andrea Facciabene’s laboratory is focussed on immunotherapy and investigation of the network of immune responses to tumors, combining basic research and clinical investigation. Our goals are to advance understanding of tumor immunology and to use new findings to develop efficacious new therapies. Our basic research includes the development of two new vaccination strategies: one uses mitochondria isolated from tumors, the other utilizes new tumor vasculature antigen. We also study regulation of immune surveillance and the tumor microenvironment by the gut microbiome. Our clinic research includes the development of new preclinical immunotherapies.

Selected Publications

Monk BJ, Facciabene A, Brady WE, Aghajanian C, Fracasso PM, Walker J, Lankes HA, Manjarrez KL, Danet-Desnoyers G, Bell-McGuinn KM, McCourt CK, Malykhin A, Hershberg RM, Coukos G: Integrative Development of a TLR8 Agonist for Ovarian Cancer Chemo-immunotherapy. Clin Cancer Res. Oct 2016.

Pierini S, Fang C, Rafail S, Facciponte JG, Huang J, De Sanctis F, Morgan MA, Uribe-Herranz M, Tanyi JL, Facciabene A*: A Tumor Mitochondria Vaccine Protects against Experimental Renal Cell Carcinoma. J Immunol 195(8):4020-7, Oct 2015 Notes: *corresponding author.

Ugel S, Facciponte JG, De Sanctis F, Facciabene A*: Targeting tumor vasculature: expanding the potential of DNA cancer vaccines. Cancer Immunol Immunother 64(10):1339-48, Oct 2015 Notes: *corresponding author.

Facciponte JG, Ugel S, De Sanctis F, Li C, Wang L, Nair G, Sehgal S, Raj A, Matthaiou E, Coukos G, Facciabene A: Tumor endothelial marker 1-specific DNA vaccination targets tumor vasculature. J Clin Invest 124(4):1497-511, Apr 2014.

Facciabene A, Santoro S, Coukos G: Know thy enemy: Why are tumor-infiltrating regulatory T cells so deleterious? Oncoimmunology 1;1(4):575-577, Jul 2012.

Facciabene A, Motz GT, Coukos G: T-regulatory cells: key players in tumor immune escape and angiogenesis. Cancer Res 1;72(9):2162-71, May 2012.

Facciabene A, Peng X, Coukos G: Tumor hypoxia promotes tolerance and angiogenesis via CCL28 and Treg cells. World Immunology Regulation Meeting, Davos, Switzerland. Mar 2012.

Facciabene A, Peng X, Coukos G: Tumor hypoxia promotes tolerance and angiogenesis via CCL28 and Treg cells. TRCCC, Seven Springs, PA. Feb 2012.

Facciabene A, Peng X, Hagemann IS, Balint K, Barchetti A, Wang LP, Gimotty PA, Gilks CB, Lal P, Zhang L, Coukos G: Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and T(reg) cells. Nature - citing articles: 11 475(7355):226-232, Jul 2011.

Alagkiozidis I, Facciabene A, Marinos Tsiatas M, Carpenito C, Benencia F, Adams S, Jonak Z, Carl H June, Powell DJ Jr, Coukos G: Time-dependent cytotoxic drugs selectively cooperate with IL-18 for cancer chemo-immunotherapy. J Transl Med 25;9:77, May 2011.

back to top
Last updated: 04/07/2017
The Trustees of the University of Pennsylvania